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Background: Pediatric osteomyelitis is a bacterial infection of bones requiring prolonged antibiotic treatment using
parenteral followed by enteral agents. Major complications of pediatric osteomyelitis include transition to chronic
osteomyelitis, formation of subperiosteal abscesses, extension of infection into the joint, and permanent bony
deformity or limb shortening. Historically, osteomyelitis has been treated with long durations of antibiotics to avoid
these complications. However, with improvements in management and antibiotic treatment, standard of care is
moving towards short durations of intravenous antibiotics prior to enteral antibiotics.
Methods/Design: The authors will perform a systematic review based on PRISMA guidelines in order to
evaluate the literature, looking for evidence to support the optimal duration of parenteral and enteral therapy.
The main goals are to see if literature supports shorter durations of either parenteral antibiotics and/or enteral
antibiotics.
Multiple databases will be investigated using a thorough search strategy. Databases include Medline, Cochrane,
EMBASE, SCOPUS, Dissertation Abstracts, CINAHL, Web of Science, African Index Medicus and LILACS. Search
stream will include medical subject heading for pediatric patients with osteomyelitis and antibiotic therapy. We
will search for published or unpublished randomized and quasi-randomized controlled trials.
Two authors will independently select articles, extract data and assess risk of bias by standard Cochrane
methodologies. We will analyze comparisons between dichotomous outcomes using risk ratios and continuous
outcomes using mean differences. 95% confidence intervals will be computed.
Discussion: One of the major dilemmas of management of this disease is the duration of parenteral therapy.
Long parenteral therapy has increased risk of serious complications and the necessity for long therapy has been
called into question. Our study aims to review the currently available evidence from randomized trials regarding
duration of both parenteral and oral therapy for pediatric acute osteomyelitis.
Trial registration: CRD42013002320Background
Description of the condition
Osteomyelitis is inflammation of the bone, usually caused
by an infectious agent. It can originate from trauma or
surgery or it can originate from hematogenous seeding.
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reproduction in any medium, provided the orsymptoms whereas subacute infections have symptoms
that persist for two weeks or more and chronic infections
last months or longer.
The incidence is 1:5,000 to 3:100,000 in the pediatric
population, and it is most common in the neonatal and
pre-school periods [1-3]. In the pre-antibiotic era, chil-
dren had a mortality rate of over 23% [4], a rate that
dropped to 3.5% with the introduction of antibiotics.
Today, in the developed world, clinicians see minimal
morbidity and almost no mortality with treatment. How-
ever, the developing world still sees a high morbidity of
osteomyelitis with challenges of inadequately treatedl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bony sequestration, and associated deformities and
pathological fractures [5,6].
In children, the most common sites of infection are
the femur (27%), tibia (24%), and pelvis (15%) [7]. Diag-
nosis is largely clinical with classical physical features of
pain, tenderness, swelling over a bony site and fever. A
variety of laboratory tests may be abnormal with raised
erythrocyte sedimentation rate (ESR) (91%), raised C-
reactive protein (CRP) (80%) and raised white blood cell
count (35%) being the most commonly examined. Radio-
logical tests may also be helpful to support the diagnosis
with the use of magnetic resonance imaging (MRI),
ultrasound, bone scan and x-rays as commonly used
modalities. Blood cultures are often done and occasion-
ally bony aspirates or biopsies at suspected site of infec-
tion are done [8].
Staphylococcus aureus is the causative agent in 80% of
cases although there are less common bacterial agents in-
cluding Haemophilus influenzae, Streptococcus pyogenes,
Escherchia coli among others [3,9]. Neonatal osteomyelitis
is a separate entity with Group B streptococcus being the
main causative agent, patients are 40% more likely to have
multiple infected sites, and they have more subtle presen-
tations. Infections are also more commonly secondary to
line sepsis [10]. Complications of osteomyelitis include the
development of a chronic bony infection, subperiosteal
abscess formation, venous thrombosis [11] and secondary
septic arthritis. Septic arthritis is a surgical emergency
requiring urgent drainage and long term complications
can include joint stiffness, joint dislocation, and limb
shortening.
Description of the intervention
Osteomyelitis requires prompt antimicrobial treatment
starting with intravenous antibiotics before transitioning
to enteral antibiotics to avoid complications that include
periosteal abscess and the development of chronic
osteomyelitis with associated bony deformities [12,13].
However, there is an absence of consensus regarding
antibiotic duration, with most sources supporting con-
servative prolonged management. Review articles and
notable pediatric textbooks recommend an average of 1
to 2 weeks of parenteral antibiotics until the C-reactive
protein normalizes, and a full 3 to 6 weeks of total anti-
biotics until the erythrocyte sedimentation rate normal-
izes [13-15]. This may require central venous catheter
insertion, a prolonged hospitalization, and extensive
cost to the family and healthcare system. Other centers
initiate several days of peripheral intravenous (IV) anti-
biotics prior to inserting a central venous catheter and
then provide 4 to 6 weeks of home IV therapy [16].
The risk of complications associated with a central line in-
clude line malfunction or displacement, catheter associatedbloodstream infection, fever with negative blood culture
results, and local skin infection [16]. As children with
osteomyelitis tend to be younger than 5 years [2,14],
anesthesia and the associated risks are necessary for the
insertion of the central line. In centers that provide
home intravenous therapy, the cost of IV antibiotics is
immensely higher than that of oral [12,13].
A systematic review published in 2002 by Le Saux
showed that a 7-day course of parenteral antibiotic was
as effective as longer durations, with the same rate of re-
currence at 6 months. However, Le Saux’s study included
observational studies primarily from the 1970s and
1980s and only one study was randomized [17]. Dartnell
et al. published a comprehensive scoping review of the
diagnosis and management of pediatric osteomyelitis in
2012 [18]. That provided a general overview of the epi-
demiology of osteomyelitis but did not specifically ad-
dress questions around the treatment of osteomyelitis in
a systematic way. Our study will ask very specific ques-
tions about treatment. We will include both English and
non-English studies and an expanded database search.
The proposed study will involve a current systematic re-
view of prospective randomized control studies to evalu-
ate if long-term parenteral therapy is required or if
short-term parenteral therapy prior to transition to en-
teral antibiotics provides safe and sufficient treatment of
osteomyelitis.
Why it is important to do this review
One of the major dilemmas of management of this dis-
ease is the duration of parenteral therapy. Long paren-
teral therapy has increased risk of serious complications
and the necessity for long therapy has been called into
question. Le Saux’s review, over 10 years ago, suggested
that shorter therapies could be efficacious and safe but
emphasized the need for higher quality evidence. We
hypothesize that new evidence has been published over
this time period. Our study aims to now review the cur-
rently available evidence from randomized trials regard-
ing duration of both parenteral and oral therapy for
pediatric acute osteomyelitis.
Methods/Design
The PRISMA statement will be used as a template for
the development and execution of this review. The sys-
tematic review protocol will be registered with the
PROSPERO database before initiation. A standardized
methodological approach to this systematic review will
be based on guidance from the Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0.
Types of studies
Studies will be limited to randomized controlled trials
and quasi-randomized controlled trials that look at an
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than 7 days, compared to previous standard of greater
than 7 days. Studies need to describe the antimicrobial
including route and duration as well as clinical outcomes
with follow-up for at least 3 months. Exclusion criteria
include retrospective studies and prospective non-
randomized studies including case series.
Types of participants
Pediatric patients younger than 18 years of age who have
been identified with osteomyelitis will be included in this
study.
Disease definition
Acute osteomyelitis is a clinical diagnosis based on
symptoms of fever, pain, and reduced weight bearing and
swelling over the affected bone. The use of laboratory tests
including positive blood culture, ESR and CRP, as well as
diagnostic imaging such as MRI, computed tomography
(CT) scan, nuclear magnetic imaging, ultrasound, or
X-ray aid in supporting the diagnosis [17-19]. For this sys-
tematic review, as defined by the authors of the primary
studies, we expect the definition of acute osteomyelitis to
include: A) clinical signs of osteomyelitis and positive
blood cultures, OR B) clinical signs and radiological sup-
port, OR C) clinical signs and positive bone culture.
Types of interventions
We will include comparative randomized trials of antibi-
otics administered either parenterally or orally, or both.
Types of outcome measures
Primary Outcome:
1. Resolution of osteomyelitis infection as determined
by resolution of symptoms including pain,
tenderness, swelling and gait abnormalities by end of
total therapy. All outcome data will be grouped at
additional discrete time periods such as 1 month,
3 months, 6 months, 1 year, and annually, if
available.
Secondary outcomes:
1. Time to resolution of infection as defined above
2. Total length of antibiotic therapy
3. Residual pain, fever, swelling and other clinical
features
4. Residual disabilities
5. Residual morbidities: includes limp, deformities, and
neurological deficits
6. Adverse events defined as mild, moderate or severe
7. Residual radiographic changes
8. Re-hospitalization for infection9. Re-initiation of therapy




The systematic review will consist of a literature search of
the databases Medline, EMBASE, SCOPUS, Cochrane
CENTRAL Database of Systematic Reviews, CINAHL,
Web of Science, Global Health, African Index Medicus
and LILACS. Relevant articles will also be hand-searched
for related publications. There will be no restrictions on
language; any relevant non-English, non-French papers
will be appropriately translated. There will be no restric-
tion on publication period or publication status. Gray lit-
erature will be searched through Dissertation Abstracts
and the library search will be repeated prior to publication
to look for new citations. The major clinical trials regis-
tries will be searched and the principle investigators for
any relevant registered RCT will be contacted to seek
sharing of any new or unpublished trial data that may be
relevant. The bibliography of all retrieved literature will be
reviewed for additional reports of trials.
Library search strategy











12. 10 not (10 and 11)





18. exp Young Adult/
19. exp Infant, Newborn/
20. exp Infant, Premature
21. exp Child, Preschool/




26. (infant* or child* or teen* or adolescen* or neonat*
or youth or young or p?ediatric*).mp.
27. (young adj2 adult*).mp.
Table 1 Inclusion and exclusion criteria
Inclusion Exclusion
Randomized Controlled trials Non- randomized trials
Quasi Randomized Trials Cohort, case-series or retrospective
studies
All languages Review articles
Acute osteomyelitis Patients >18 years
Children 0 to 18 years Chronic or sub-acute osteomyelitis,









follow-up for 3 months
Intervention other than antibiotic
Identify the anti-microbial and its
route
Route of antimicrobial unclear
Identify duration of therapy Duration of parenteral or enteral
therapy unclear
Outcome after 3 months follow-up
stated or inferred as clinical cure,
failure or relapse
Follow-up not documented
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36. (child* or adolescent* or infant* or pediatric* or
paediatric*).jn,jw.
37. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or
31 or 32 or 33 or 34 or 35 or 36
38. exp Osteomyelitis/
39. exp Bone Diseases/
40. exp Bone Diseases, Infectious/
41. exp Infection/
42. 39 and 41
43. exp Staphylococcal Infections/and (bone* or
osteo*).mp. [mp = title, abstract, original title, name
of substance word, subject heading word, protocol
supplementary concept, rare disease supplementary
concept, unique identifier]
44. exp Streptococcal Infections/and (bone* or osteo*).
mp. [mp = title, abstract, original title, name of
substance word, subject heading word, protocol
supplementary concept, rare disease supplementary
concept, unique identifier]
45. 38 or 40 or 42 or 43 or 44 or ′9′.mp. or ′10′.mp.
[mp = title, abstract, original title, name of
substance word, subject heading word, protocol
supplementary concept, rare disease supplementary
concept, unique identifier]
46. osteomyelitis.mp.
47. (bone adj3 infect*).mp.











59. exp Clavulanic Acids/
60. (Anti-Bacterial Agent* or antibiotic* or Penicillin*
or Cephalosporin* or Macrolid* or Quinolon* or
Aminoglycosid* or Rifampin* or Carbapenem* or
Glycopeptid* or Tetracyclin* or Lincosamid* or
Clavulinic Acid*).mp.
61. antisyphilitic drugs.mp. or exp Antitreponemal
Agents/62. hetacillin.mp.
63. cephalospor*.mp.
64. exp Lincomycin/or lincomycin.mp.
65. clavulanic acid.mp. or exp Clavulanic Acid/
66. beta lactamases.mp. or exp beta-Lactamases/
67. penicillinases.mp. or exp Penicillinase/
68. or/48-67
69. 45 and 68
70. 13 and 69
71. limit 70 to “all child (0 to 18 years)”
72. 37 and 70
73. 71 or 72
74. 45 and 73
75. 13 and 45 and 68
76. 38 or 40 or 42 or 43 or 44 or 46 or 47
77. 13 and 37 and 68 and 76
78. limit 77 to randomized controlled trial
79. limit 77 to case reports
80. 77 not 79
81. 77 not 80Study selection process
The literature search results will be uploaded to a refer-
ence manager EndNote X5 (Thomson Reuters, New York,
NY, United States). Study selection will be done in two
stages. Initially, abstracts and titles will be screened inde-
pendently by two reviewers (CG and JO) against inclusion
and exclusion criteria (Table 1). Both reviewers will then
independently review potentially relevant papers in their
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form. All reviewed and excluded articles will be recorded
on an Excel spreadsheet, with reasons being noted for ex-
clusions. If there is any discordance between the authors,
the review authors will resolve any disagreements by con-
sensus or through discussion with a third reviewer (SC),
who will evaluate and decide on the contended study.
Data collection
Both authors (CG and JO) will use a standardized custom-
ized data extraction form based on and adapted from the
forms supplied by the Cochrane Bone, Joint and Muscle
Trauma Group. Initially the form will be piloted to ensure
that data collection is consistent between both reviewers.
Data to be extracted includes signs and symptoms of
osteomyelitis, blood culture results, radiological support,
duration of intravenous antibiotics (7 days) and qualitative
total duration, duration of follow-up, whether patients
were followed for 6 months after presentation, how many
patients were lost to follow-up, whether central venous
lines were inserted, and method of randomization.
Risk of bias assessment
Each reviewer (CG and JO) will independently assess the
risk of bias in each primary trial using the Cochrane
Risk of Bias tool as described in the Cochrane Handbook
for Systematic Reviews of Interventions 5.1. Each param-
eter will be judged as either low risk of bias, high risk of
bias, or unclear risk of bias. When possible, authors will
be contacted to clarify unclear criteria. Assessment of
bias will be compared between authors and any discrep-
ancies will be resolved through discussion and consen-
sus, or through a decision by the third reviewer (SC).
During data synthesis, data will be pooled together and
evaluated as a whole. The data will then be re-evaluated
using a sensitivity analysis to see the impact of studies
with high risk of bias.
Domains of importance will include:
 Random sequence generation
 Allocation concealment
 Blinding (participants, assessors, care providers)
 Incomplete outcome data
 Selective outcome reporting
 Other sources of bias
Data analysis
A statistician (BV) from the Alberta Research Centre for
Health Evidence (ARCHE) and who is experienced with
systematic review methodology has been consulted for
the project. For each study, we will analyze comparisons
between dichotomous outcomes using risk ratios (RR)
and between continuous outcomes using mean differ-
ences. We will compute the 95% confidence intervals(CI) for all estimates. Where populations, interventions
and outcomes are sufficiently clinically homogenous,
results will be statistically pooled using a DerSimonian-
Laird random effects model; fixed effects will be con-
sidered in a sensitivity analysis. This will be done using
the Mantel-Haenszel method for RR and the inverse
variance method for pooling mean differences. In cases
where the outcomes are measured in different scales, a
standardized mean difference (SMD) will be used to
pool results, rather than a weighted mean difference
(WMD). Review Manager version 5.0.22 (The Cochrane
Collaboration, Copenhagen, Denmark) and Stata ver-
sion 7.0 (Stata Corporation, College Station, TX, USA)
will be used for all these analyses. In the event that
studies cannot be pooled, evidence tables will be pro-
duced and a narrative summary of the results will be
presented.
Dealing with missing data
Authors of primary studies will be contacted to clarify
any unclear or missing data.
Assessment of heterogeneity
Heterogeneity among studies will be measured using the
I2 statistic, which describes the percentage of total vari-
ation across trials due to heterogeneity rather than sam-
pling error. In cases of substantial heterogeneity, subgroup
and meta-regression analyses will be performed if the
number of studies is sufficient to warrant these analyses.
Heterogeneity will be considered to be statistically signifi-
cant if I2 is over 25%.
Publication bias
Where possible, we will also analyze publication bias
both visually using the funnel plot and quantitatively
using Egger’s regression test.
Subgroup analysis
Subgroup analysis will be conducted for the primary out-
come to assess how the effect of treatment may vary in
clinically relevant subgroups. We anticipate clinical het-
erogeneity and thus the following a-priori clinically rele-
vant subgroups have been identified for consideration:
Different age groups (0 to 11 months, 1 to 5 years, 6 to
12 years and 13 to 18 years old)
Microbiological cause (methicillin-resistant
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Sensitivity analyses will be conducted to assess the ro-
bustness of the findings across study quality (low risk of
bias versus high risk or unclear risk), parallel versus
crossover trial designs, random effects versus fixed ef-
fects analyses, and randomized controlled trials versus
quasi-randomized trials.
Discussion
This systematic review will update the literature on best
practice in pediatric osteomyelitis. A similar study was
conducted in 2002 and found that shorter courses of
parenteral therapy had similar cure rates to prolonged
courses but the results were limited to cohort studies.
We will conduct a comprehensive search reviewing an
estimated 3,400 studies, compared to 284 reviewed by
Le Saux et al. and, we hope that relevant randomized
controlled trials will have been published in the past
decade.
This review will allow statistical analysis of outcomes
to prove whether short- or long-term parenteral antibi-
otics are better for clinical outcomes. If short-term par-
enteral antibiotics are superior, this will provide
evidence to minimize hospital stay and avoid the inser-
tion of central venous catheters. If long-term parenteral
antibiotics are superior, this will provide justification to
families for the strain of prolonged health care systems
involvement for therapy. We hope to also find similar
data regarding the optimal duration of enteral therapies.
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